Please assess the completion status of the following clinical trial:

Trial Title: Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with an acute myocardial infarction with ST elevation~* Subject with an acute myocardial infarction without ST elevation~* Subject with unstable angina (progressive angina during past 2 weeks, negative cardiac markers, Trop T \< 0,014μg/l~* First time of taking Brilique~* ≥ 18 years~* Possibility to take a blood sample before administration of Brilique~* Signed Informed Consent, signed by subject or authorized representative, able and willing to provide written informed consent for study participation~Exclusion Criteria:~* Active haemorrhage~* Moderate or severe liver failure with coagulopathy~* Pregnancy and lactation~* A history of an intra cerebral haemorrhage~* Patient is HIV positive and treated with Ritonavir and /or Atazanavir~* Patient treated with vitamin K antagonist or with a new oral anti coagulant~* Hypersensitivity to ticagrelor or any of the excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- starting with ticagrelor (Type: OTHER): Patients, after CPR because of an ACS, will receive 2 crushed tablets of ticagrelor (180mg) through a gastric tube. After this dose twice a day 90mg is given for the duration of 1 year. The 1st blood sample is taken before administration. In total 10 blood samples are taken for determination of platelet aggregation and plasma concentrations.~When patients receive a semi-urgent CABG, ticagrelor has been interrupted for 3 days. Postoperative the patients get crushed tablets of ticagrelor, the 1st dose will be 90mg, and every 12h 90mg is given, for the duration of 1 year. The 1st blood sample is taken before the 1st dose. In total 9 blood samples are taken for determination of platelet aggregation and plasma concentrations.

Based on this trial design, predict the completion outcome and termination type (if applicable).